A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Clinical trial NCT07271667 · RECRUITING
Trial details
- NCT number
- NCT07271667
- Sponsor
- Curis, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-23
- Primary completion
- 2027-11-01
- Enrollment
- 108
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.